Article

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma

2025-07-31

Abstract excerpt

<h4>ABSTRACT</h4> Glioblastoma (GBM) cancer stem cells (CSCs) contribute to tumor recurrence, treatment resistance, and dismal clinical outcomes. Genetic and pharmacological evidence suggests that the nuclear scaffolding protein WD-repeat containing protein 5 (WDR5) is a therapeutic vulnerability of the CSC population. However, previously reported WDR5 inhibitors display low permeability and are unable to penetra...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 04ec5184-ab7f-56d6-8ed6-99792feaa971
DOI: 10.1101/2025.07.29.667410

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of GlioblastomaDOI 10.1101/2025.07.29.667410Read

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastomaSemantic proximity Read

Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastomaSemantic proximity Read

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read

Design and Biological Activity of a Novel Brain Penetrant Urea Compound Against GlioblastomaSemantic proximity Read

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatmentSemantic proximity Read

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell modelsSemantic proximity Read

A multistep in silico approach identifies potential glioblastoma drug candidates via inclusive molecular targeting of glioblastoma stem cellsSemantic proximity Read

Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression dataSemantic proximity Read

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesSemantic proximity Read

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in GlioblastomaSemantic proximity Read

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read

ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Semantic proximity Read